Inovio Biomedical Corp (NYSEMKT:INO)

CAPS Rating: 2 out of 5

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar kurdlingsvoice (< 20) Submitted: 6/12/2014 3:11:36 PM : Outperform Start Price: $8.79 INO Score: +24.26

Catalysts!

Recs

0
Member Avatar egnarops (46.94) Submitted: 6/11/2014 5:06:55 PM : Outperform Start Price: $8.82 INO Score: +24.48

Inovio is on the cusp of radically changing how we approach the treatment of cancer, malaria , all strains of flu, mers and many other deadly diseases .

Recs

0
Member Avatar butters83 (46.10) Submitted: 4/17/2014 11:39:45 AM : Outperform Start Price: $13.68 INO Score: -24.03

This a pure speculative play. They have some interesting drugs in their pipeline. Like most biotechs, though, good news means huge profits, and bad news means near total loss.

Recs

0
Member Avatar Jared1048 (< 20) Submitted: 3/20/2014 3:50:38 PM : Outperform Start Price: $15.10 INO Score: -31.87

The product line up that they are going to come out with are second to none! Look into this company and you will soon see its extremely undervalued! checkout there expected earnings in 2017

Recs

1
Member Avatar ColossalSlug (< 20) Submitted: 3/13/2014 3:42:44 PM : Outperform Start Price: $13.64 INO Score: -25.28

Inovio has roughly a dozen vaccines in current trial that are very promising as indicated in previous studies. In addition to the keen abilities in R&D by some of the best researchers in the business, their partnerships are solid and will be extremely beneficial in the development and FDA application areas. The scope, success, and magnitude of what this company has in the pipeline - some with phase 2 trial results in 2014 - is just too hard to dismiss. Yes, investments in INO will be volatile and data driven, but we should be seeing fairly consistent stair-stepping to the upside for years to come.

Recs

0
Member Avatar SetMyPeopleFree (33.34) Submitted: 3/7/2014 12:08:32 PM : Outperform Start Price: $13.96 INO Score: -25.61

I bought a few hundred shares under $3, and added enough over 3 up to 3.55 to average $3. My biggest failure is not getting much more at $2.38 a couple weeks ago, or any at all on intra-day quick drop to $3 even last week. The science is mankind changing, and the CEO is not only genius in his field, but a Wharton MBA. This is a 10 bagger by next year, and perhaps a possible 500x even here near 3.50.

Recs

0
Member Avatar pjlullo (< 20) Submitted: 2/24/2014 11:04:40 AM : Outperform Start Price: $14.16 INO Score: -28.13

Pharms are going to be hot this year

Recs

0
Member Avatar samuelbeh (< 20) Submitted: 2/20/2014 9:33:24 AM : Outperform Start Price: $11.44 INO Score: -10.63

Expecting positive results from clinical trials.

Recs

0
Member Avatar TerryHoodSr (51.12) Submitted: 2/19/2014 9:23:22 AM : Outperform Start Price: $8.60 INO Score: +20.63

upside potential, TP $4

Recs

0
Member Avatar JungleDoctor (< 20) Submitted: 2/12/2014 11:59:15 PM : Outperform Start Price: $10.48 INO Score: -2.84

If malaria vaccine succeeds, will be a world changer

Recs

0
Member Avatar SqwiiTrader (51.54) Submitted: 1/21/2014 3:24:16 AM : Outperform Start Price: $10.04 INO Score: +3.65

Flu play

Recs

0
Member Avatar jdowning22 (< 20) Submitted: 1/18/2014 8:06:56 PM : Outperform Start Price: $10.04 INO Score: +2.76

New drugs in the pipeline for quite awhile.

Recs

0
Member Avatar slammasters98 (< 20) Submitted: 11/23/2013 7:35:31 PM : Outperform Start Price: $8.68 INO Score: +18.92

Important phase studies ending or ended and with crucial data coming out in the next 8 months that can blow up this stock like it did in Sept. when it ran to 3.00. New positive data will drive additional partnership talks, more funding, and more institutional buying

Recs

0
Member Avatar Brooer (< 20) Submitted: 11/17/2013 9:18:56 PM : Outperform Start Price: $7.96 INO Score: +30.05

Inovio recently made a deal with Roche Holdings AG for exclusive rights to just two of its many products still in early investigative stages.This deal could eventually be worth hundreds of millions and is only the first of what will hpoefully be many deals with big pharma in the near future.

Recs

3
Member Avatar zzlangerhans (99.69) Submitted: 8/16/2013 12:21:28 AM : Underperform Start Price: $6.12 INO Score: -64.71

Letting go of a green thumb on a tiny biopharma that's turned itself into a sudden multibagger is always a tough decision. I've dropped out so many times content with a couple of hundred points only to see the stock continue to rocket upwards, throwing hundreds of missed points in my face. In general, I console myself by thinking that at least I'm getting the story right even if I'm clueless on the timing. Yeah, right.

The Inovio spike happened quickly, and I just didn't have time to stay on top of it. The intraday peak of three would have been a great moment to jump off my green thumb and probably short the stock as well if shares were available, since there was clearly no precipitant except the requisite Seeking Alpha article timed to juice a manipulated price spike. Once I missed the spike, I held for a few days to see if there would be a second act but only succeeded in wiping another 100 points of my score. And of course my exit signaled the end of the price dive, at least for now.

Despite buyout speculation, the cast of characters in Inovio's pipeline is very familiar to anyone who has followed the company through year after year of slow progress and trial failures. PENNVAX, VGX-3100, SynCon ... is it still 2007? I hope at least a few long-suffering holders took the opportunity to cash out and move on to greener pastures, but I fear they're determined to redeem their 90% losses.

Recs

0
Member Avatar remrem44 (30.89) Submitted: 8/5/2013 1:28:54 PM : Outperform Start Price: $5.00 INO Score: +105.81

5 in less 6 months

Recs

0
Member Avatar SAnitaB (< 20) Submitted: 8/2/2013 3:12:18 PM : Outperform Start Price: $8.14 INO Score: +20.74

Great trials results on several projects recently

Recs

0
Member Avatar NoDoughBro (70.45) Submitted: 7/31/2013 10:30:40 AM : Outperform Start Price: $8.08 INO Score: +20.87

Always too late for the party.

Recs

0
Member Avatar stardog900 (< 20) Submitted: 7/27/2013 2:08:23 PM : Outperform Start Price: $6.00 INO Score: +68.17

If trials are successful, as is anticipated, this stock should outperform the S&P 500 over the next year or two.

Recs

2
Member Avatar whoodatstockhot (87.95) Submitted: 7/10/2013 12:31:40 PM : Outperform Start Price: $5.78 INO Score: +72.54

Pennvax-B trial extremely exciting, continued success will provide explosive upside. Nice risk/reward below $2.00. No secondary risk.

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners


Advertisement